Povofortay (povorcitinib)

Where it stands

Povofortay (povorcitinib), from Incyte Biosciences Distribution B.V., received a CHMP positive opinion on 17 September 2026. The proposed indication is the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults. The records show the status as "Opinion", and no approval date is recorded, so the product is not yet authorised in the EU.

A CHMP positive opinion is a recommendation to the European Commission, not a marketing authorisation. The Commission normally adopts a legally binding decision based on that opinion. Only after that decision can the product be marketed across the EU/EEA.

The records give an expected EC decision date of 23 November 2026. This is an estimate, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date and the actual decision could come earlier or later.

Regulatory pathway and designations

The records show a CHMP opinion, which means the application went through the EMA's centralised procedure. A Commission decision following that opinion would cover all EU Member States, plus Iceland, Liechtenstein and Norway. The records do not give the submission date, the assessment timetable or the type of application, so the length and details of the review cannot be assessed here.

No designations are recorded for this product. The records do not show orphan, PRIME, accelerated assessment or paediatric-related status. This should be read as "none recorded", not as confirmation that none exist.

The only official milestone in the records is the CHMP positive opinion. The Commission decision is a projection.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse event information, warnings, contraindications, risk management plan details or post-authorisation commitments, so no conclusions about the product's benefit-risk profile can be drawn from them.

For the safety profile, readers should consult the Summary of Product Characteristics, the risk management plan summary and the EPAR once the EMA publishes them. These will set out any additional monitoring, risk minimisation measures or post-authorisation studies. Pharmacovigilance obligations, including routine safety reporting by the marketing authorisation holder, would apply after authorisation.

What to watch

The main near-term event is the Commission decision, estimated at 23 November 2026 but not officially scheduled. Watch for the decision itself and the resulting marketing authorisation date, which would update the status from "Opinion" to authorised.

Also watch for publication of the EPAR and product information. These documents would show the final wording of the indication, any conditions or restrictions, and the safety and risk management detail missing from the records. The records do not cover launch timing, pricing, reimbursement or national access, so those points cannot be assessed.